{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+of+care+treatment&page=30", "query": { "intervention": "standard of care treatment", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 9585, "total_pages": 959, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+of+care+treatment&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=standard+of+care+treatment&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:56:35.902Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03824587", "title": "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "Tenapanor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Phosphate Binder Agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardelyx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 236, "start_date": "2019-02-28", "completion_date": "2019-07-17", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Lynwood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03824587" }, { "nct_id": "NCT05482893", "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastroesophageal Junction Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Colorectal Cancer" ], "interventions": [ { "name": "Spevatamig (PT886)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "CAPOX", "type": "DRUG" }, { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "TAS 102", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine Combined With Cisplatin", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2023-03-15", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 11, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05482893" }, { "nct_id": "NCT07722767", "title": "A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML (Acute Myeloid Leukemia)" ], "interventions": [ { "name": "CLN-049", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cullinan Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-10-15", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07722767" }, { "nct_id": "NCT04075864", "title": "Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Behavioral Counseling and Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-12-01", "completion_date": "2025-12-10", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04075864" }, { "nct_id": "NCT06174987", "title": "A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "T-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-01-05", "completion_date": "2028-01-17", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 2, "location_summary": "Miami, Florida • Durham, North Carolina", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06174987" }, { "nct_id": "NCT03180021", "title": "Dynamic Imaging of Variation in Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "MRI", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "RILITE Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2018-03-13", "completion_date": "2020-10-02", "has_results": false, "last_update_posted_date": "2021-10-04", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 6, "location_summary": "Aurora, Colorado • New York, New York • Columbus, Ohio + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03180021" }, { "nct_id": "NCT03104504", "title": "A System of Safety (SOS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Suicide" ], "interventions": [ { "name": "Suicide Risk Screening", "type": "BEHAVIORAL" }, { "name": "Safety Planning", "type": "BEHAVIORAL" }, { "name": "Care transition facilitation", "type": "BEHAVIORAL" }, { "name": "A Lean Implementation Strategy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 493756, "start_date": "2016-10-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03104504" }, { "nct_id": "NCT07183319", "title": "Circulating Tumor DNA Response In Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Pembrolizumab & Enfortumab Vedotin (PEV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-01-19", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07183319" }, { "nct_id": "NCT01268319", "title": "CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Atherosclerosis", "Myocardial Infarction", "Coronary Plaque Embolization" ], "interventions": [ { "name": "Embolic Protection Device (EPD)", "type": "DEVICE" }, { "name": "Intracoronary Spectroscopy and Ultrasonic Evaluation", "type": "DEVICE" }, { "name": "Angioplasty and Stent Implant", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Infraredx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2011-05", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2017-06-12", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01268319" }, { "nct_id": "NCT04248244", "title": "Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Palliative Care", "type": "OTHER" }, { "name": "FACT-MM questionnaire", "type": "OTHER" }, { "name": "HADS questionnaire", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-02-17", "completion_date": "2022-10-26", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-15T18:56:35.902Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04248244" } ] }